NCT06279923

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Clinical Study of Targeting CD19-BAFF CAR-T Cells in the Treatment of Autoimmune Diseases

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases.

Detailed description

In this study, 45 patients with Autoimmune Diseases include Systemic Lupus Erythematosus、Systemic sclerosis、Dermatomyositis、Immune nephritis and Neuromyelitis optica were proposed to undergo CD19-BAFF CAR-T cell therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of CD19-BAFF CAR-T cell therapy for Autoimmune Diseases; At the same time, on the basis of expanding the sample size, more safety data on CD19-BAFF CAR-T cell treatment for Autoimmune Diseases were accumulated, including rare and delayed complications.

Conditions

• Autoimmune Diseases

Interventions

Type	Name	Description
BIOLOGICAL	CD19-BAFF Targeted CAR T-cells	Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2024-04-15
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2024-02-28
• Last updated: 2024-04-09

Locations

1 site across 1 country: China